John M. Kirkwood
Experienced in Olfactory Neuroblastoma

Dr. John M. Kirkwood

Hematology Oncology
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Experienced in Olfactory Neuroblastoma
UPMC
UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John M. Kirkwood, MD, is a professor of medicine, dermatology, and clinical and translational science at the University of Pittsburgh School of Medicine and the Clinical and Translational Science Institute at the University of Pittsburgh. Dr. Kirkwood directs the Melanoma Center at UPMC Hillman Cancer Center and specializes in melanoma research and the prevention and early detection of melanoma, as well as the treatment of advanced disease and adjuvant therapy of resectable disease.

Dr. Kirkwood is rated as an Experienced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Melanoma, Melanoma of the Eye, Metastatic Uveal Melanoma, and Uveal Melanoma.

His clinical research consists of co-authoring 333 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Yale University
Residency
Yale New Haven Hospital
Specialties
Hematology Oncology
Licenses
Specialist in PA
Board Certifications
American Board Of Internal Medicine
American Board Of Internal Medicine
Fellowships
Dana Farber Cancer Institute
Hospital Affiliations
Magee Womens Hospital Of Upmc Health System
Upmc Horizon
Upmc Presbyterian Shadyside
Upmc Passavant
Upmc Mercy
Languages Spoken
English
German
Italian
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center
5115 Centre Avenue, Hillman Cancer Center, Pittsburgh, PA 15232
Call: 724-299-1493

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 Therapy
A Phase I/II Study of PI3Kγδ Inhibitor Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma Who Have Progressed on Anti-PD1 Therapy
Enrollment Status: Terminated
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Duvelisib
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Trametinib, Spartalizumab (PDR001)
Study Phase: Phase 3
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Enrollment Status: Withdrawn
Publish Date: July 24, 2024
Intervention Type: Drug
Study Drugs: IMCgp100, Durvalumab, Tremelimumab
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
A Multicenter Phase 2, Open Label Study of Intratumoral Tavokinogene Telseplasmid (Tavo, pIL-12) + Electroporation With Pembrolizumab in Patients With Stage 3/4 Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Enrollment Status: Unknown
Publish Date: March 27, 2023
Intervention Type: Biological, Device
Study Drugs: Tavokinogene Telseplasmid, Pembrolizumab
Study Phase: Phase 2
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma
Enrollment Status: Terminated
Publish Date: January 03, 2022
Intervention Type: Drug
Study Drugs: Pembrolizumab, Vemurafenib, Cobimetinib
Study Phase: Phase 1
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma
Enrollment Status: Completed
Publish Date: April 03, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 10 Less Clinical Trials

333 Total Publications

A Review of Melanoma-Reply.
A Review of Melanoma-Reply.
Journal: JAMA
Published: December 11, 2025
View All 333 Publications
Similar Doctors
Dan P. Zandberg
Advanced in Olfactory Neuroblastoma
Dr. Dan P. Zandberg
Hematology Oncology
Advanced in Olfactory Neuroblastoma
Dr. Dan P. Zandberg
Hematology Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Hillman Cancer Center, 
Pittsburgh, PA 
 (0.1 miles away)
412-530-6124
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dan P. Zandberg, MD, is an associate professor of medicine and a medical oncologist/hematologist, specializing in the treatment of head and neck and thyroid cancers. He is the Director of the Head and Neck and Thyroid Cancer disease sections for the division of Hematology/Oncology and the Medical Oncology Co-Leader of the UPMC Hillman Head and Neck Cancer Program. He is also the physician lead for the second floor Hillman Cancer Center clinic. His main research focus is in the development of clinical trials with immunotherapy to improve patient outcomes. Recent awards include the 2019 National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award, 2020 Leo Criep, M.D. Excellence in Patient Care Award, and 2020/2021 Castle Connolly Regional Top Doctor. Dr. Zandberg is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Oral Squamous Cell Carcinoma, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Squamous Cell Lung Carcinoma.

Experienced in Olfactory Neuroblastoma
Dr. Sigurdur R. Petursson
Hematology Oncology | Hematology | Oncology
Experienced in Olfactory Neuroblastoma
Dr. Sigurdur R. Petursson
Hematology Oncology | Hematology | Oncology
160 Hollywood Dr Fl 2, 
Butler, PA 
 (31.6 miles away)
724-282-6175
Languages Spoken:
English
See accepted insurances

Sigurdur Petursson is a Hematologist Oncology specialist and a Hematologist in Butler, Pennsylvania. Dr. Petursson is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Acute Mountain Sickness, Hereditary Coproporphyria, Variegate Porphyria, and Polycythemia Vera.

Jason J. Luke
Experienced in Olfactory Neuroblastoma
Dr. Jason J. Luke
Hematology Oncology | Oncology
Experienced in Olfactory Neuroblastoma
Dr. Jason J. Luke
Hematology Oncology | Oncology

University Of Pittsburgh Physicians

5230 Centre Ave, Suite 509, 
Pittsburgh, PA 
 (0.4 miles away)
412-623-2458
Languages Spoken:
English
See accepted insurances

Jason Luke is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

VIEW MORE OLFACTORY NEUROBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kirkwood's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Kirkwood is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Distinguished
  • Melanoma of the Eye
    Dr. Kirkwood is
    Distinguished
    . Learn about Melanoma of the Eye.
    See more Melanoma of the Eye experts
  • Advanced
  • Metastatic Uveal Melanoma
    Dr. Kirkwood is
    Advanced
    . Learn about Metastatic Uveal Melanoma.
    See more Metastatic Uveal Melanoma experts
  • Uveal Melanoma
    Dr. Kirkwood is
    Advanced
    . Learn about Uveal Melanoma.
    See more Uveal Melanoma experts
  • Experienced
  • Anal Cancer
    Dr. Kirkwood is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Brain Tumor
    Dr. Kirkwood is
    Experienced
    . Learn about Brain Tumor.
    See more Brain Tumor experts
  • Choroid Plexus Carcinoma
    Dr. Kirkwood is
    Experienced
    . Learn about Choroid Plexus Carcinoma.
    See more Choroid Plexus Carcinoma experts
  • Dehydration
    Dr. Kirkwood is
    Experienced
    . Learn about Dehydration.
    See more Dehydration experts
  • Familial Prostate Cancer
    Dr. Kirkwood is
    Experienced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Glioma
    Dr. Kirkwood is
    Experienced
    . Learn about Glioma.
    See more Glioma experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.